AbbVie Inc. Announces Quarterly Dividend of $1.64 per Share
ByAinvest
Friday, Sep 5, 2025 11:04 am ET1min read
ABBV--
AbbVie, a member of the S&P Dividend Aristocrats Index, has consistently increased its dividend for at least 25 consecutive years, reflecting its strong financial performance and stability. The company's mission is to discover and deliver innovative medicines that address serious health issues across key therapeutic areas, including immunology, oncology, neuroscience, and eye care, as well as its Allergan Aesthetics portfolio [1].
In addition to its dividend announcement, AbbVie has been actively expanding its product pipeline. Recently, the company agreed to pay up to $1.2 billion to acquire Gilgamesh's short-acting psychedelic bretisilocin, which is being explored for the treatment of psychiatric diseases, including major depressive disorder (MDD) [2]. This acquisition highlights AbbVie's growing interest in hallucinogenic drugs for mental health conditions.
AbbVie is also making progress with its lymphoma therapy, epcoritamab, in partnership with Genmab. New data from a mid-stage trial suggests that the bispecific antibody can be safely administered in an outpatient setting, potentially improving access to treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [3].
With a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries, AbbVie continues to focus on its core markets while expanding its global footprint [1].
References:
[1] https://finance.yahoo.com/news/abbvie-declares-quarterly-dividend-130700697.html
[2] https://www.nature.com/articles/d41573-025-00149-0
[3] https://seekingalpha.com/news/4491809-abbvie-updates-data-genmab-partnered-lymphoma-drug
AbbVie Inc. declares a quarterly dividend of $1.64 per share. The company specializes in therapeutic drug research and development, with a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries.
AbbVie Inc. (NYSE: ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to shareholders of record as of October 15, 2025. This latest dividend increase underscores the company's commitment to shareholder value, as it has raised its dividend by 310% since its inception in 2013 [1].AbbVie, a member of the S&P Dividend Aristocrats Index, has consistently increased its dividend for at least 25 consecutive years, reflecting its strong financial performance and stability. The company's mission is to discover and deliver innovative medicines that address serious health issues across key therapeutic areas, including immunology, oncology, neuroscience, and eye care, as well as its Allergan Aesthetics portfolio [1].
In addition to its dividend announcement, AbbVie has been actively expanding its product pipeline. Recently, the company agreed to pay up to $1.2 billion to acquire Gilgamesh's short-acting psychedelic bretisilocin, which is being explored for the treatment of psychiatric diseases, including major depressive disorder (MDD) [2]. This acquisition highlights AbbVie's growing interest in hallucinogenic drugs for mental health conditions.
AbbVie is also making progress with its lymphoma therapy, epcoritamab, in partnership with Genmab. New data from a mid-stage trial suggests that the bispecific antibody can be safely administered in an outpatient setting, potentially improving access to treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [3].
With a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries, AbbVie continues to focus on its core markets while expanding its global footprint [1].
References:
[1] https://finance.yahoo.com/news/abbvie-declares-quarterly-dividend-130700697.html
[2] https://www.nature.com/articles/d41573-025-00149-0
[3] https://seekingalpha.com/news/4491809-abbvie-updates-data-genmab-partnered-lymphoma-drug
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet